Objective: To evaluate the efficacy of tamsulosin or solifenacin for treatment of Lower Urinary Tract Symptoms (LUTS) due to an indwelling ureteral stent. Material & Method: In this study, we enrolled 24 patients who had polyurethane DJ-stent inserted for urinary stone disease or ureteral stenosis. Patients were divided into 3 equal groups as follows and study medications were started on postoperative day 7. Group I received tamsulosin 0,4 mg once daily, group II received solifenacin 5 mg once daily, and group III only received placebo. LUTS were evaluated using International Prostatic Symptoms Score (IPSS) questionnaire at 7 and 14 days after the procedure and stent insertion. The evaluation of IPSS score included not only total score but also irritative and obstructive subcores. Results: All 24 patients fulfilled the inclusion and exclusion criteria, mean age of tamsulosin group was 54,3 years old, solifenacin group was 45,3 years old and placebo was 46,7 years old. There was significant difference in the total IPSS and irritative subscores between groups who received either tamsulosin or solifenacin (group I and II), whereas the obstructive subscore showed a difference though not statistically significant. Conclusion: Tamsulosin or solifenacin significantly improved irritative symptoms of LUTS in patients with an indwelling ureteral stent.Keywords: Lower urinary tract symptoms, DJ-stent, tamsulosin, solifenacin.
Lam SJ, Gupta M. Ureteral stents; Urinary stone disease, the Practical Guide to Medical and Surgical Management. Humana Press. 2007; 25: 465–88.
Joshi BH, Stainthorpe A, MacDonagh PR, Keeley FX, Timoney GA. Indwelling ureteral stent: Evaluation of symptoms, quality of life and utility. The Journal of Urology. 2003; 169: 1065–9.
Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Valkarakis M. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? The Journal of Urology. 2006; 67: 35–9.
Lim SJ, Sul KC, Song HK, Na GY, Shin HJ, Oh HT, et al. Chages in urinary symptoms and tolerance due to long-term ureteral double- J stenting. INJ. 2010; 14: 93–9.
Joshi BH, Okeke A, Newns N, Keeley Jr, Timoney G. Characterization of urinary symptoms in patiens with ureteral stents. Journal of Urology. 2002; 59: 511–6.
Damiano R, Autorino R, De Sio M, Cantiello F, Quarto G, Perdona S, et al. Does the ureteral stents impact urinary symptoms and quality of life? A Prospective Randomized Study. Journal of Europen Urology. 2005; 48: 673–8.
Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo MI, D’Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: A Prospective Study. Journal of Endourology. 2008; 22(4).
Wang CJ, Huang SW, Chang CH. Effect of tamsulosin on lower urinary tract symptoms due to double J stent: A Prospective Study. Urol Int. 2009; 83(1): 66–9.
Pricop C, Ciuta C, Mischianu D, Rusu F. Is there a role for tamsulosin or solifenacine in the management of urinary tract symptoms in patienst with double-J stent. Journal of Urology. 2009; 74.
Park SJ, Jung S, Lee J, Rim J. The effects of tolterodine extended release and alfuzosine for treatment of double-J stent related symptoms. Journal of Urology. 2009; 11: 1913–7.
Navanitmitkul N, Lojanapiwat B. Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: Arandomize controlled study. The Journal of International Medical Research. 2010; 38: 1436–41.
Leibovici D, Cooper A, Lindner A, Otrowsky R, Kleinmann J, Velikanov S, et al. Ureteral stents: Morbidity and impact on quality of life. 2005. IMAJ; 7: 491–4.